Marker for auxiliary screening of neurodegenerative cognitive impairment and application thereof

By using phosphorylated Tau181 protein and Aβ40 as markers, combined with flow fluorescence technology, an efficient screening system was developed, which solved the problem of missed patients in early stages of Alzheimer's disease screening, and achieved high sensitivity and accuracy The screening effect is suitable for the screening needs of Chinese people.

CN118914047APending Publication Date: 2024-11-08TIANJIN KINGMED CENT FOR CLINICAL CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411138237.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of easy-to-access, economical, sensitive, specific and simple biomarkers and screening systems in the screening of Alzheimer's disease has led to difficulties in missed examinations and diagnosis in early stages, especially in the Chinese population. Way.

Method used

Using phosphorylated Tau181 protein and Aβ40 as markers, combined with flow fluorescence technology to develop an efficient screening system, achieve high specificity, sensitivity and accuracy through plasma detection to assist in screening of neurodegenerative cognitive impairment, and design reference intervals and detection systems , use the mean ± standard deviation method to build a screening system to improve screening accuracy and sensitivity.

Benefits of technology

It has achieved high sensitivity and accurate screening for patients with Alzheimer's disease and its prodromal stage, with screening accuracy reaching 95.8%, recall rate reaching 88.5%, and reduced testing costs and equipment requirements, which are suitable for community screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914047A_ABST
    Figure CN118914047A_ABST
Patent Text Reader

Abstract

The invention relates to a marker for auxiliary screening of neurodegenerative cognitive impairment and application of the marker. The marker comprises a phosphorylated Tau181 protein. Based on a flow type fluorescence detection technology, it is found that the levels of phosphorylated Tau181 protein (p-tau181), A beta 40 and A beta 42 / A beta 40 have significant differences in healthy people, AD-derived MCI patients, AD patients and SIVD patients, an auxiliary diagnosis system is further developed, a diagnosis reference interval is designed, and the screening accuracy and sensitivity reach 87.1% and 82.3% respectively.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of medical diagnosis, and relates to a marker for assisting in the screening of neurodegenerative cognitive disorders and an application thereof. Background Art

[0002] Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. The development of AD is divided into three stages: preclinical AD, AD-induced mild cognitive impairment (MCI) and AD-induced dementia. It is the most common cause of degenerative cognitive impairment, and its pathogenesis has not yet been fully elucidated. Currently, the screening and evaluation methods for Alzheimer's disease mainly include clinical evaluation, imaging examination and laboratory examination. Clinical evaluation is a routine examination with average performance, and requires more professional and systematic training and long-term growth to enable a clinician to have systematic and standardized cognitive evaluation capabilities; imaging evaluation, MR or CT are mostly non-specific, and there may be no obvious atrophy and signs of involvement in the early stage. AD has an insidious onset and progresses gradually from the preclinical stage with intact cognition to the prodromal stage of mild cognitive impairment (MCI) and then to the dementia stage. The entire course of the disease can be as long as 20 to 30 years. The launch of new AD monoclonal antibody treatment drugs, which are currently highly anticipated, has also shown the best therapeutic effect in the early clinical stage. However, once entering the dementia stage, the patient's daily living ability will be greatly impaired. There is currently no effective treatment for AD in the dementia stage, so early diagnosis and early intervention are particularly important.

[0003] In the current diagnosis and treatment system, as a screening marker, scale assessment is highly expected in early diagnosis and screening due to its low price, but it currently has the following shortcomings: First, facing the huge community population base, there is a lack of clinical physicians with corresponding assessment qualifications and experience, which may lead to different scores; second, due to the huge differences in education levels, the system assessment scale introduced from abroad may not be suitable for the effective assessment of the Chinese population, and there is a lack of effective scale assessment methods for community populations in clinical practice; third, over-reliance on scale scores can easily lead to missed detection of preclinical patients and fail to effectively screen the applicable population. At present, the gold standard for Alzheimer's disease detection is Aβ-PET and Tau-PET brain imaging or cerebrospinal fluid testing. Cerebrospinal fluid testing requires puncture, patient compliance is poor, PET is expensive, and only a few cognitive centers have the ability to detect, making it difficult to popularize.

[0004] In summary, there is an urgent need for biomarkers and screening systems that are easily accessible, economical, sensitive, specific, simple and easy to use to improve the screening level and achieve effective screening of preclinical and AD patients. Summary of the invention

[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides a marker for assisting the screening of neurodegenerative cognitive disorders and its application, develops an efficient screening system, and achieves high specificity, sensitivity and accuracy to assist the screening of neurodegenerative cognitive disorders.

[0006] To achieve this object, the present invention adopts the following technical solutions:

[0007] In a first aspect, the present invention provides a marker for assisting in screening of neurodegenerative cognitive disorders, wherein the marker comprises phosphorylated Tau181 protein (p-tau181).

[0008] In the present invention, based on the flow fluorescence technology platform, an in-depth analysis of multicenter samples from China was conducted, and it was found that there were significant differences among healthy people, AD-derived MCI patients, AD patients, and SIVD (subcorticalischemic vascular disease) patients. The plasma phosphorylated Tau181 protein concentration in AD-derived MCI patients, AD-derived dementia patients, and SIVD patients was significantly higher than that in healthy people, and the increase in AD-derived MCI patients and AD-derived dementia patients was more obvious. It was further verified that it can be used to achieve high specificity, sensitivity and accuracy to assist in the screening of neurodegenerative cognitive disorders.

[0009] Preferably, the markers further include Aβ42 and / or Aβ40.

[0010] The present invention also found that the ratio of Aβ40 or Aβ42 to Aβ40 concentration (Aβ42 / Aβ40) was significantly different among healthy people, AD-derived MCI patients, AD patients, and SIVD patients. The Aβ40 concentration in patients was significantly increased, while Aβ42 / Aβ40 was significantly decreased.

[0011] Preferably, the neurodegenerative cognitive disorders include Alzheimer's disease-induced mild cognitive impairment and Alzheimer's disease-induced dementia.

[0012] In a second aspect, the present invention provides use of the detection substance for assisting in screening markers for neurodegenerative cognitive disorders described in the first aspect in the preparation of a product for assisting in screening for neurodegenerative cognitive disorders.

[0013] Preferably, the detection substance includes reagents and / or devices for detecting the markers for assisting in screening of neurodegenerative cognitive disorders as described in the first aspect.

[0014] Preferably, the reagents and / or devices include flow fluorescence detection reagents and / or devices.

[0015] In a third aspect, the present invention provides a product for assisting in the screening of neurodegenerative cognitive impairment, and the product includes reagents and / or devices for detecting the markers for assisting in the screening of neurodegenerative cognitive impairment described in the first aspect.

[0016] In the present invention, the screening based on the markers can be used as a primary screening assessment to help further screen suspicious populations that need to improve PET or cerebrospinal fluid AD tests. If both plasma p-tau181 and Aβ40 are positive, it is recommended to use PET or cerebrospinal fluid analysis for subsequent confirmatory assessment, and comprehensive analysis should be combined with medical history, family history, neurological scales, etc. If the levels of plasma p-tau181 and Aβ40 are not consistent with the clinical manifestations of MCI and AD, further examinations can be considered to identify other etiologies.

[0017] In a fourth aspect, the present invention provides a system for assisting in the screening of neurodegenerative cognitive impairment. The input data of the system is the concentration of the markers for assisting in the screening of neurodegenerative cognitive impairment described in the first aspect. The criteria for determining positive for Alzheimer's dementia are:

[0018] The concentration of phosphorylated Tau181 protein > 2.051 pg / mL and / or Aβ40 > 123.283 pg / mL;

[0019] The criteria for determining positive for subcortical ischemic cerebrovascular disease are:

[0020] 1) 1.086 < p-tau181 ≤ 2.051 pg / mL and Aβ40 ≤ 123.283 pg / mL, and / or,

[0021] 2) 86.441 < Aβ40 ≤ 123.283 pg / mL and p-tau181 ≤ 2.051 pg / mL.

[0022] In the present invention, based on the mined markers, the mean ± standard deviation method is further used to construct an auxiliary screening system, design the reference intervals for phosphorylated Tau181 protein and Aβ40, and use a flow-through fluorescence platform for detection. After removing outliers, the overall screening accuracy and sensitivity reach 87.1% and 82.3% respectively, and the precision for screening AD and AD-derived MCI patients can reach 95.8%, and the sensitivity can reach 88.5%. High-sensitivity and accurate detection can be achieved based on only two markers.

[0023] The present invention also provides a construction method for the system for assisting in the screening of neurodegenerative cognitive impairment, and the construction method includes:

[0024] Preferably, the method comprises: 1) collecting data: collecting data of the markers in healthy human samples; 2) calculating the mean: calculating the mean (Mean) of this set of data; 3) calculating the standard deviation: calculating the standard deviation (SD) of the data; 4) determining the reference interval: using the mean plus two times the standard deviation (Mean+2SD) and the mean minus two times the standard deviation (Mean-2SD) to determine the upper and lower limits of the reference interval. 5) constructing a system to assist in screening for neurodegenerative cognitive disorders, explaining the reference interval, in the case of normal distribution, theoretically about 95% of the "normal" population will fall within this interval, so if an individual's test results are outside this interval, they may need further evaluation or testing.

[0025] In a fifth aspect, the present invention provides a device for assisting in screening neurodegenerative cognitive disorders, the device comprising a detection unit and a determination unit;

[0026] The detection unit is used to perform the following steps:

[0027] Detecting the concentration of the marker for assisting in screening for neurodegenerative cognitive disorders described in the first aspect in the sample to be tested;

[0028] The determination unit is used to perform the following steps:

[0029] Auxiliary diagnosis is performed according to the system for auxiliary screening of neurodegenerative cognitive disorders described in the fourth aspect.

[0030] Preferably, the sample to be tested includes a plasma sample.

[0031] Preferably, the detection method comprises flow cytometry.

[0032] The present invention is developed based on the flow fluorescence detection method, and a screening system and device based on the flow fluorescence detection results are designed, which significantly improves the detection sensitivity and specificity, and has a low detection bottleneck, low instrument and equipment requirements, low reagent cost, easier promotion, and a short detection cycle, making it more suitable for auxiliary community screening.

[0033] In a sixth aspect, the present invention provides a computer-readable storage medium having a computer program or instructions stored thereon, which, when executed by a processor, implements the functions of the device for assisting in screening for neurodegenerative cognitive disorders as described in the fifth aspect.

[0034] In a seventh aspect, the present invention provides a computer device comprising a memory and a processor, wherein the memory stores a computer program or instructions, and when the computer program or instructions are executed by the processor, the functions of the device for assisting in screening for neurodegenerative cognitive disorders described in the fifth aspect are realized.

[0035] Compared with the prior art, the present invention has at least the following beneficial effects:

[0036] The present invention finds that the levels of phosphorylated Tau181 protein (p-tau181), Aβ40 and Aβ42 / Aβ40 are significantly different in healthy people, AD-derived MCI patients and AD patients, and SIVD patients based on flow fluorescence detection technology. Based on phosphorylated Tau181 protein (p-tau181) and Aβ40, an auxiliary diagnosis system is further developed, and the diagnostic accuracy of healthy people, AD and AD-derived MCI and SIVD patients can reach 87.1%, the accuracy of screening AD and AD-derived MCI patients can reach 95.8%, and the recall rate can reach 88.5%. Highly sensitive and accurate detection can be achieved based on only two markers, and the flow platform has low detection bottleneck, low instrument and equipment requirements, low reagent cost, easy promotion, short detection cycle, and is more suitable for auxiliary community screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 It is a box plot of the concentration distribution of phosphorylated Tau181 protein groups;

[0038] Figure 2 It is the box plot of Aβ40 group concentration distribution;

[0039] Figure 3 Box plot of Aβ42 / Aβ40 group concentration distribution. DETAILED DESCRIPTION

[0040] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.

[0041] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0042] Flow fluorescence technology is a detection method that has attracted much attention in recent years. It is widely used in the fields of cytokine detection. Due to its high throughput, strong sensitivity and stable performance, it has begun to be widely used in clinical practice. It can accurately quantify the level of proteins with extremely low content in peripheral blood. At present, there is still a lack of reference intervals for multi-center Chinese populations for phosphorylated Tau181 protein (p-tau181) in China, and it has not been effectively used for clinical application detection. The present invention analyzes multi-center normal human samples from China based on a flow fluorescence technology platform, and establishes reference intervals for phosphorylated Tau181 protein (p-tau181) and Aβ40, which can effectively assist in screening for neurodegenerative cognitive disorders.

[0043] Example 1

[0044] This example analyzes the levels of phosphorylated Tau181 protein (p-tau181), Aβ40, and Aβ42 / Aβ40 in healthy people, AD-derived MCI (mild cognitive impairment) and AD (Alzheimer's disease) people, and SIVD (subcortical ischemic vascular disease).

[0045] 110 healthy samples, 26 AD-derived MCI (mild cognitive impairment) patient samples and AD patient samples (AD-derived dementia) samples, and 19 SIVD patient samples were collected from multiple centers across the country. The levels of phosphorylated Tau181 protein (p-tau181), Aβ40, and Aβ42 / Aβ40 were detected based on the flow cytometry technology platform. The specific detection process includes the preparation of calibrators and test samples:

[0046] 1. Dilute the rewarmed 10× washing buffer 10 times with pure water to make 1× washing buffer;

[0047] 2. Calculate the number of samples n (n = number of calibrators 9 + quality control tube 1 + number of test samples);

[0048] 3. Take the capture microsphere mixture from the kit, vortex for 30 seconds, take n×25μL (0.1-0.2 times more can be taken appropriately) in a test tube and mark it;

[0049] 4. Take out the calibration tube from the kit, transfer it to a test tube, add 1000μL sample diluent, let it stand for 15 minutes, and mark it as the highest calibration concentration; pour the quality control into a 15mL centrifuge tube (make sure each lyophilized pellet is in the centrifuge tube, be careful not to damage the pellet) and add 5mL sample diluent, let it stand for 15 minutes (shake and mix before use);

[0050] 5. Take 8 test tubes and mark them as 0, 1:128, 1:64, 1:32, 1:16, 1:8, 1:4, and 1:2 respectively; add 200 μL of sample diluent to each tube;

[0051] 6. Mix the highest concentration calibrator tube by oscillation. Pipette 200 μL of sample from the highest concentration calibrator tube into the 1:2 tube by pipetting 5 times and oscillating for 20 seconds. Then take 200 μL of sample from the 1:2 tube into the 1:4 tube by pipetting 5 times and oscillating for 20 seconds. Repeat this process until the 1:128 tube.

[0052] 7. Take n sample tubes and mark them in sequence as calibration tubes: 0, 1, 2, ... 8, quality control tube: contorl1, sample tubes: Test1, Test2 ... Test (n-10);

[0053] 8. Add 25 μL of reaction buffer to all tubes (mix thoroughly before use);

[0054] 9. After the capture microsphere mixture is shaken and mixed, add 25 μL to all calibration tubes, quality control tubes and sample tubes respectively;

[0055] 10. According to the above table, add 25 μL of the corresponding concentration of calibrator to each calibrator tube, add 25 μL of quality control product to the quality control tube, and add 25 μL of the sample to be tested to each sample tube (the frozen-thawed sample must be completely thawed and mixed thoroughly before adding);

[0056] 11. Add 25 μL of detection antibody reagent to all sample tubes;

[0057] 12. After all the sample tubes are shaken and mixed for 3 seconds, incubate at 2-8℃ in the dark for 18 hours;

[0058] 13. Add 25 μL SA-PE to all sample tubes, shake and mix for 3 seconds, and incubate at room temperature in the dark for 30 minutes;

[0059] 14. After incubation, add 1 mL of 1× wash buffer to each tube, shake and mix for 3 seconds, then centrifuge at 400×g for 5 minutes, discard the supernatant and use absorbent paper to remove the residual liquid at the tube mouth;

[0060] 15. Add 100-150 μL 1× washing buffer to each tube, vortex and resuspend before loading onto the machine (for example, the stop condition for collection of p-tau181 is 300 particles).

[0061] 5. Getting on the Machine

[0062] 6. Results Analysis

[0063] Import the data obtained on the computer into FCAP (3.0.1), draw the calibration curve, and measure the results of the samples to be tested (the original data needs to be copied back).

[0064] The results of phosphorylated Tau181 protein concentration in healthy subjects, AD-derived MCI patients, AD patient samples, and SIVD patient samples are as follows Figure 1 As shown, it can be seen that the concentration of phosphorylated Tau181 protein in AD-derived MCI patients, AD patient samples, and SIVD patient samples is significantly higher than that in healthy people, while the concentration of Tau181 protein in AD-derived MCI patients and AD patient samples is significantly higher than that in SIVD patients.

[0065] The results of Aβ40 concentration in healthy subjects, AD-derived MCI patients, AD patient samples, and SIVD patient samples are as follows Figure 2 As shown, it can be seen that the Aβ40 protein concentration in AD-derived MCI patients, AD patient samples, and SIVD patient samples is significantly higher than that in healthy people, while the Aβ40 protein concentration in AD-derived MCI patients and AD patient samples is significantly higher than that in SIVD patient samples.

[0066] The levels of Aβ42 / Aβ40 in healthy subjects, AD-derived MCI patients, AD patient samples, and SIVD patient samples are shown in Figure 2. Figure 3 As shown, the levels of Aβ42 / Aβ40 in AD-derived MCI patients, AD patient samples, and SIVD patient samples were significantly lower than those in healthy people, while the levels of Aβ42 / Aβ40 in AD-derived MCI patients and AD patient samples were similar to those in SIVD patient samples.

[0067] In summary, the levels of phosphorylated Tau181 protein (p-tau181), Aβ40, and Aβ42 / Aβ40 were significantly different in healthy people, AD-induced MCI patients, AD patients, and SIVD patients, and have the potential to be used for auxiliary diagnosis.

[0068] Example 2

[0069] This embodiment designs an auxiliary diagnosis system.

[0070] Based on the sample data of Example 1, this example further designs an auxiliary diagnosis system based on the mean ± standard deviation method, and establishes the reference interval for healthy people of phosphorylated Tau181 protein (p-tau181) as 0.002 ≤ p-tau181 ≤ 1.086 pg / mL, and the reference interval for healthy people of Aβ40 as 40.029 ≤ Aβ40 ≤ 86.441 pg / mL. When p-tau181 > 2.051 pg / ml or Aβ40 > 123.283 pg / mL, AD-derived MCI (mild cognitive impairment) and AD (Alzheimer's disease) can be screened out. When 1.086 < p-tau181 ≤ 2.051 pg / mL and Aβ40 ≤ 123.283 pg / mL or 86.441 < Aβ40 ≤ 123.283 pg / mL and p-tau181 ≤ 2.051 pg / mL, SIVD (subcortical ischemic vascular disease) can be screened out.

[0071] Example 3

[0072] This example verifies the diagnostic efficacy of the diagnostic system in Example 2.

[0073] Based on the diagnostic system in Example 2, 110 healthy person samples, 26 AD-derived MCI (mild cognitive impairment) patient samples and AD (Alzheimer's disease) patient samples, and 19 SIVD (subcortical ischemic vascular disease) patient samples are grouped for prediction, and the accuracy, precision, recall rate and F1 value of each group and the sorted classification are calculated.

[0074] The calculation formulas for each diagnostic index are as follows:

[0075]

[0076]

[0077]

[0078]

[0079] Among them, TP represents the number of samples that are actually positive and are correctly classified as positive, TN represents the number of samples that are actually negative and are correctly classified as negative, FP represents the number of samples that are actually negative but are misclassified as positive, and FN represents the number of samples that are actually positive but are misclassified as negative.

[0080] The results are shown in Table 1. The diagnostic accuracy for healthy people, AD, AD-derived MCI and SIVD patients can reach 87.1%, the screening precision for AD and AD-derived MCI patients can reach 95.8%, and the recall rate can reach 88.5%.

[0081] Table 1. Performance of diagnostic system prediction results

[0082] Accuracy Accuracy Recall F1 value AD+MCI - 0.958 0.885 0.920 SIVD - 0.500 0.684 0.578 Control population - 0.952 0.900 0.925 total 0.871 0.803 0.823 0.807

[0083] In summary, the present invention found that the levels of phosphorylated Tau181 protein (p-tau181), Aβ40 and Aβ42 / Aβ40 were significantly different in healthy people, AD-derived MCI patients and AD patients, and SIVD patients based on flow fluorescence detection technology. Based on phosphorylated Tau181 protein (p-tau181) and Aβ40, an auxiliary diagnosis system is further developed, and the diagnostic accuracy of healthy people, AD and AD-derived MCI and SIVD patients can reach 87.1%, and the accuracy of screening for AD and AD-derived MCI patients can reach 95.8%, and the recall rate can reach 88.5%. Highly sensitive and accurate detection can be achieved based on only two markers, and the flow platform has low detection bottlenecks, low instrument and equipment requirements, low reagent costs, easier promotion, short detection cycle, and is more suitable for auxiliary community screening.

[0084] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. Use of a detection substance for a marker for assisting in screening neurodegenerative cognitive impairment in the preparation of a product for assisting in screening neurodegenerative cognitive impairment; The marker includes phosphorylated Tau181 protein and Aβ40; The detection substance includes a reagent and / or device for detecting the marker; The reagent and / or device includes a flow fluorescence detection reagent and / or device.

2. The use according to claim 1, characterized in that: The neurodegenerative cognitive impairment includes Alzheimer's disease-related mild cognitive impairment, Alzheimer's disease-related dementia, and subcortical ischemic cerebrovascular disease.

3. A product for assisting in screening of neurodegenerative cognitive disorders, characterized in that: The product includes a reagent and / or device for detecting the marker for assisting in screening neurodegenerative cognitive impairment described in claim 1.

4. A system for assisting in screening neurodegenerative cognitive disorders, characterized in that: The input data of the system is the concentration of the marker for assisting in screening neurodegenerative cognitive impairment described in claim 1, and the criteria for determining positive for Alzheimer's disease-related mild cognitive impairment and Alzheimer's disease dementia are: Concentration of phosphorylated Tau181 protein > 2.051 pg / mL and / or Aβ40 > 123.283 pg / mL; The criteria for determining positive for subcortical ischemic cerebrovascular disease are: 1) 1.086 < p-tau181 ≤ 2.051 pg / mL and Aβ40 ≤ 123.283 pg / mL, and / or, 2) 86.441 < Aβ40 ≤ 123.283 pg / mL and p-tau181 ≤ 2.051 pg / mL.

5. The method for constructing a system for assisting in screening neurodegenerative cognitive disorders according to claim 4, characterized in that: The construction method includes the following steps: 1) Collect data: Collect data of the marker in healthy human samples; 2) Calculate the average value: Calculate the average value of the collected data; 3) Calculate the standard deviation: Calculate the standard deviation of the collected data; 4) Determine the reference interval; 5) Construct a system for assisting in screening neurodegenerative cognitive impairment according to the reference interval.

6. The method for constructing a system for assisting in screening neurodegenerative cognitive disorders according to claim 5, characterized in that: The method for determining the reference interval includes: Using the average value plus twice the standard deviation and the average value minus twice the standard deviation as the upper and lower limits of the reference interval, respectively.

7. A device for assisting in screening neurodegenerative cognitive disorders, characterized in that: The device includes a detection unit and a determination unit; The detection unit is used to perform including: Detect the concentration of the marker for assisting in screening neurodegenerative cognitive impairment described in claim 1 in a sample to be tested; The determination unit is used to perform including: Perform auxiliary diagnosis according to the system for assisting in screening neurodegenerative cognitive impairment described in claim 4.

8. The device for assisting in screening neurodegenerative cognitive disorders according to claim 7, characterized in that: The sample to be tested includes plasma. Preferably, the detection method includes flow fluorescence detection method.

9. A computer-readable storage medium having a computer program or instruction stored thereon, characterized in that: The computer program or instruction, when executed by a processor, implements the functions of the device for assisting in screening neurodegenerative cognitive impairment described in claim 7 or 8.

10. A computer device comprising a memory and a processor, wherein the memory stores a computer program or instruction, wherein: The computer program or instruction, when executed by a processor, implements the functions of the device for assisting in screening neurodegenerative cognitive impairment described in claim 7 or 8.

Citation Information

Cited By

  • Mass spectrum flow data acquisition and processing method

    CN119534284A

  • Application of flow type detection reagent in bleeding risk grade classification product of tumor diseases

    CN120778688A